Cabozantinib is produced by which company

Cabozantinib is a multi-target tyrosine kinase inhibitor mainly used for the treatment of advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and differentiated thyroid cancer (DTC). By inhibiting VEGFR, MET, AXL and other signaling pathways, it not only effectively blocks tumor angiogenesis, but also inhibits cancer cell proliferation and metastasis. It is currently one of the important targeted therapeutic drugs for a variety of advanced solid tumors.

The original drug of cabozantinib is developed and produced by**EXELIXIS Inc.**, a U.S.-based biopharmaceutical company known for the development of innovative anti-cancer drugs. Since its establishment, EXELIXIS has focused on the research and development of targeted tumor treatment drugs. Its research and development philosophy emphasizes high selectivity, multi-target inhibition and breakthroughs in drug resistance mechanisms.

The drug is produced in the United States, and the production process strictly followsGMP (Good Manufacturing Practice) standards. From raw material synthesis to tablet preparation, every link is strictly monitored to ensure drug quality, stability and efficacy consistency. EXELIXIS has established a complete supply chain system globally and supplies original drugs to many countries and regions such as North America, Europe, and Asia through the United States and overseas distribution channels. Its pharmaceutical packaging, labeling and storage conditions all comply with international standards to ensure patient safety during use.

In addition to the production of original drugs,EXELIXIS also licenses with partners around the world, enabling some regions to produce and sell generic versions through authorization to increase the accessibility of drugs. This type of cooperation not only ensures that the drug ingredients are consistent with the original drugs, but also reduces patient treatment costs to a certain extent. In the domestic market, although the price of original drugs is relatively high, formal channels can ensure that the source of drugs is safe and reliable, and are included in the scope of medical insurance reimbursement, helping patients better obtain treatment opportunities.

Reference:https://en.wikipedia.org/wiki/Cabozantinib